Earnings call transcript: Planet 13’s Q4 2025 shows revenue growth

Planet 13 reported Q4 2025 revenue of $25.2M, up 8% sequentially, with gross margin recovering to 44.6% from 21.3% in Q3 and adjusted EBITDA loss narrowing to $0.3M (a $3.8M sequential improvement). The company ended Q4 with $15.6M cash, completed exit from California (reducing run-rate revenue by ~$2.5–3.0M/qtr) and expects gross margins >50% beginning Q1 2026 and positive EBITDA for the year. Key near-term catalysts/risk: Florida BHO lab regulatory approval pending, Clark County hemp retail regulation likely to benefit Nevada operations, and continued Las Vegas tourism headwinds that could constrain SuperStore recovery.

Analysis

The operational moves (portfolio pruning in low-return jurisdictions and consolidation of cultivation) create more than a simple margin arithmetic story: they convert a volatile revenue base into a thinner-but-higher-quality cash flow stream that is easier to model and finance. Expect incremental margin gains to flow disproportionately to free cash flow because near-term capex needs are small — that makes the company more sensitive to modest topline recovery and regulatory wins than to further large-scale cost cuts.

Two regulatory catalysts are asymmetric for this stock: local enforcement that curbs intoxicating hemp outlets will re-route tourist dollars back into licensed retail channels, and any federal rescheduling removes a structural tax drag that compounds upside across margins, balance-sheet metrics and M&A optionality. Both are binary or timing-sensitive, so the market is likely discounting much of the upside until outcomes are explicit — creating a scenario where near-term volatility can be high but upside concentrated if catalysts land.

Second-order winners include branded extract partners and wholesale suppliers in the company’s target state: once a BHO line is approved, branded SKUs and licensing deals can scale faster than new brick-and-mortar builds, raising AUR and improving shelf economics for the operator. Conversely, multi-state peers with entrenched California exposure are relatively disadvantaged in the short to medium term because they cannot realize the same margin recovery absent portfolio restructuring or regulatory relief.

Primary risks: regulatory timing risk (weeks-to-quarters), continued tourist softness in destination retail that depresses conversion rates, and illiquidity/financing constraints if operating cadence slips. The tradeable window is catalytic (approval decisions, county enforcement effective dates, and the first clean post-restructuring quarterly prints) — treat positions as event-driven with clear stop discipline.

Key Decisions for Investors

• Accumulate Planet 13 (PLNH / PLNHF) over 6–12 weeks up to 1–2% NAV as a tactical, event-driven position; horizon 6–12 months to capture BHO approval and local enforcement flow. Risk: regulatory delay or another operational slip; set hard stop at -40% and scale out 50% on a 2.5–3x move.
• Create a sector-isolating pair: long PLNH / short MJ ETF (MJ) notional-neutral for 6–9 months to extract company-specific upside (margin convertibility and local enforcement) while hedging macro cannabis beta. Size small (0.5–1% NAV) given execution/borrow and ETF basis risk.
• Buy a defensive put spread on a large, CA-heavy MSO (e.g., TLRY put spread expiring 6–9 months) to profit from a relative underperformance if investors re-rate CA exposure; use proceeds from small ATM puts to limit premium paid. Reward: asymmetric if market rotates away from CA-exposed names; risk: sector rally or positive CA-specific news.
• If liquid, add a low-cost asymmetric kicker: buy long-dated (9–15 month) out-of-the-money calls on PLNH where available, size <0.5% NAV. Rationale: captures convexity from rescheduling upside or timely BHO approval with limited downside (premium).